Navigation Links
MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Date:9/29/2010

ffers to buy any securities of MAP Pharmaceuticals and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the conduct and completion of clinical trials, and relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent o
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... About Chronic Lymphocytic Leukemia ... increased production of lymphocytes. It has been observed that ... spread to other parts of the body. This leukemia ... slow buildup of the cancerous cells. During the course ... liver, and lymph nodes. The course of the disease ...
(Date:9/2/2015)... STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye, today announced that its Board of Directors has ... Mr. Wall was formerly the General Counsel ... firm, for more than nine years. Mr. Wall is currently ... the Corporate Governance Committee and member of the Audit Committee, ...
(Date:9/2/2015)... and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced the addition of ... November 26-27, 2015)" conference to their offering. ... key areas of pharmaceutical regulatory affairs in China ... Macau and Taiwan and ... gaining and maintaining a successful Marketing Authorisation in the region ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... The New Jersey Patient Care and Access Coalition (NJPCAC), representing ... and their families to speak out to preserve prostate cancer ... recommended healthy men should no longer receive prostate-specific antigen (PSA) ... This decision was made by a panel that does ...
... The number of Americans who are obese will increase to ... than twenty years, a recent study says. 1 800 ... designed for individuals suffering from obesity and associated diseases resulting ... the centers and professionals we work with, is to attain ...
Cached Medicine Technology:NJ Docs Say Cancer Detection Tool Saves Lives 21-800-GET-THIN Agrees With Report Calling for Better Eating Habits 2
(Date:9/2/2015)... ... ... Telehealth represents a growing trend among Blue Cross and Blue Shield plans, with ... 12 Blues plan clients. The September 2015 issue of The AIS Report ... executives at Capital Blue Cross, whose telehealth services will launch next year. Published independently ...
(Date:9/2/2015)... ... ... Date and time: Oct. 3, 2015, 9 a.m. to 4 p.m. ... Athyn, Pa 19009 , Cost: $50 per person; includes lunch , The Quakertown, Pa.-based ... Sam Keen based on his new book which he co-authored with his son, Gifford ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an innovative ... its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone app ... A leader in health technology, RxNT was one of the first to build ...
(Date:9/2/2015)... ... 02, 2015 , ... Care Providers and their medical billing ... include EOBs, payments, and payment related documents. AD-EOB A/R helps them sort, index ... billing, with one efficient process and interface,“ stated Rich Caproni, AliusDoc’s Director of ...
(Date:9/2/2015)... ... September 02, 2015 , ... Good health and a good ... Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New Jersey Golf Foundation ... foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3
... devices help babies survive, thrive into adulthood, study shows , ... that was typically fatal three decades ago is no longer ... allow babies to survive well into adulthood, researchers report. , ... New England Journal of Medicine compares the effectiveness of ...
... of the National Academies will convene a regional meeting ... Chicago to discuss the rapidly rising rates of diabetes ... Conference on Diabetes and Obesity will bring together leading ... preventive measures and policy issues will be discussed by ...
... hormone that triggers the need for a night,s rest may ... News) -- Brain injuries can disrupt the body,s production of ... study suggests. , "We,ve known that people often have problems ... much about the exact causes of these problems," study author ...
... ... Product(s) Used in a Wide Variety of Arthroscopic Tenodesis Knee Procedures Such as: ACL, ... ... today it has received FDA 510k clearance for product(s) used in a wide variety ...
... , WEDNESDAY, May 26 (HealthDay News) -- Researchers report that ... the brain in mice -- a finding that could help ... who suffer from Alzheimer,s disease and stroke. , Removing clots ... blood to flow unimpeded, since blockages can lead to a ...
... Scientists are reporting development of a fast, simple, inexpensive ... workplaces may cause skin allergies in people -- a ... study appears in ACS, Chemical Research in Toxicology ... his colleagues note the existence of public sentiment against ...
Cached Medicine News:Health News:Progress Made Against Once-Fatal Heart Defect 2Health News:Progress Made Against Once-Fatal Heart Defect 3Health News:UIC to host Institute of Medicine Meeting on diabetes and obesity 2Health News:Brain Injuries May Lead to Sleep Woes 2Health News:KFx Medical Corporation Announced Today It Has Received FDA 510k Clearance for Product(s) Used in a Wide Variety of Knee Procedures 2Health News:Brain Cells May Serve as Clot-Busters 2
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Medicine Products: